Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
CEO Bids Farewell to Mitsubishi Chemical after Group Revamp
Jean-Marc Gilson, president and CEO of Mitsubishi Chemical Group, says he is heading towards the exit door with “a great sense of accomplishment” as he sees the company’s drastic restructuring efforts coming to fruition. Mr Gilson, a Belgian who was…
To read the full story
Related Article
- Manabu Chikumoto to Helm Mitsubishi Chemical Group from April
December 25, 2023
- Mitsubishi Tanabe to Refine Growth Scenario, Expand Overseas Operations under New Leadership
May 24, 2023
- Mitsubishi Chemical to Fix “Overextension” of Pharma Biz, Focus on 4 Therapeutic Areas, Japan/US: CEO
February 28, 2023
- Mitsubishi Chemical Taps Belgium-Born Gilson as Its First Foreign CEO
October 26, 2020
BUSINESS
- Takeda Reports Additional Benefits for Narcolepsy Drug Oveporexton
June 17, 2026
- Astellas CEO’s Pay Rises to 733 Million Yen in FY2025: Securities Report
June 17, 2026
- Torii Starts PIII Trial of Cantharidin for Common Warts
June 17, 2026
- Ono CEO’s Pay Climbs to 260 Million Yen
June 16, 2026
- Six Eisai Executives Took Home Over 100 Million Yen in FY2025
June 16, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…